Squarepoint
VERV

Squarepoint’s Verve Therapeutics VERV Stock Holding History

Squarepoint’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-73,810
Closed -$360K – 4735
2024
Q2 		$360K Sell
73,810
-9,990
-12% -$62.8K ﹤0.01% 3309
2024
Q1 		$1.11M Sell
83,800
-160,885
-66% -$2.13M ﹤0.01% 2514
2023
Q4 		$3.41M Buy
244,685
+219,155
+858% +$2.72M 0.01% 1640
2023
Q3 		$339K Buy
25,530
+10,362
+68% +$167K ﹤0.01% 3073
2023
Q2 		$284K Sell
15,168
-110,272
-88% -$1.84M ﹤0.01% 3005
2023
Q1 		$1.81M Buy
125,440
+82,945
+195% +$1.62M 0.01% 1487
2022
Q4 		$822K Buy
+42,495
New +$1.13M ﹤0.01% 1963
2022
Q3 		– Sell
-40,417
Closed -$618K – 3474
2022
Q2 		$618K Buy
40,417
+11,035
+38% +$171K ﹤0.01% 1897
2022
Q1 		$670K Buy
+29,382
New +$840K ﹤0.01% 1835
2021
Q3 		– Sell
-31,253
Closed -$1.88M – 3461
2021
Q2 		$1.88M Buy
+31,253
New +$1.3M 0.01% 1221

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Squarepoint's VERV Position: Q3 2024 in Review

Squarepoint sold out of Verve Therapeutics (VERV) in Q3 2024, closing a stake of 73,810 shares — an estimated $360K sold.

Squarepoint first reported a position in VERV in Q2 2021 and held it in 10 quarters. The position peaked at $3.41M in Q4 2023. 174 funds tracked by Wall St. Rank hold VERV as of Q3 2024.

  • Squarepoint reported no remaining Verve Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Squarepoint sold 73,810 Verve Therapeutics shares in Q3 2024, an estimated $360K.
  • Squarepoint first reported a position in Verve Therapeutics in Q2 2021 and held it in 10 quarters.
  • Squarepoint's Verve Therapeutics position peaked at $3.41M in Q4 2023.
  • 174 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2024.

Based on Squarepoint's 13F filing for Q3 2024, filed 14 Nov 2024.